MeSH term
Frequency | Condition_Probility | Humans | 1072 | 0.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Adult | 567 | 0.0 |
Aged | 174 | 0.0 |
Aged, 80 and over | 42 | 0.0 |
Aquaporins/*urine | 13 | 65.0 |
Argipressin/*blood | 199 | 97.0 |
Female | 540 | 0.0 |
Heart Failure, Congestive/*metabolism | 2 | 7.0 |
Male | 707 | 0.0 |
Middle Aged | 325 | 0.0 |
Osmolar Concentration | 212 | 29.0 |
Pressoreceptors/physiology | 7 | 70.0 |
Research Support, Non-U.S. Gov't | 539 | 0.0 |
Sodium/blood | 57 | 52.0 |
Angiotensin II/pharmacology | 6 | 8.0 |
Argipressin/pharmacology | 34 | 75.0 |
Carbachol/pharmacology | 2 | 2.0 |
Culture Techniques | 6 | 1.0 |
Dose-Response Relationship, Drug | 48 | 0.0 |
In Vitro | 35 | 0.0 |
Nitroglycerin/pharmacology | 2 | 11.0 |
Vasoconstriction/drug effects | 7 | 18.0 |
Vasodilation/drug effects | 3 | 5.0 |
Vasodilator Agents/*pharmacology | 3 | 6.0 |
Base Sequence | 27 | 0.0 |
Exons | 7 | 0.0 |
Receptors, Vasopressin/*genetics | 4 | 16.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 58 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 169 | 0.0 |
Social Behavior | 2 | 10.0 |
Animals | 218 | 0.0 |
Argipressin/analysis/*physiology | 2 | 100.0 |
Oxytocin/analysis/*physiology | 2 | 100.0 |
Argipressin/*pharmacology | 50 | 96.0 |
Corticotropin/*blood | 25 | 39.0 |
Corticotropin-Releasing Hormone/adverse effects/*pharmacology | 2 | 66.0 |
Random Allocation | 5 | 1.0 |
Argipressin/blood | 115 | 90.0 |
Blood Glucose/metabolism | 16 | 2.0 |
Amino Acid Sequence | 37 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Hela Cells | 5 | 0.0 |
Models, Molecular | 7 | 0.0 |
Molecular Sequence Data | 49 | 0.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Substrate Specificity | 3 | 0.0 |
English Abstract | 44 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Vasoconstrictor Agents/*therapeutic use | 2 | 50.0 |
Blood Pressure/drug effects | 70 | 12.0 |
Blood Proteins/metabolism | 6 | 2.0 |
Injections, Intravenous | 14 | 2.0 |
Injections, Intraventricular | 13 | 9.0 |
Kinetics | 42 | 0.0 |
Neurons/drug effects/physiology | 2 | 9.0 |
Peptides/administration & dosage/*pharmacology | 3 | 33.0 |
Rats | 89 | 0.0 |
Rats, Sprague-Dawley | 19 | 0.0 |
Vasopressins/blood/*metabolism | 5 | 83.0 |
Argipressin/*metabolism | 29 | 87.0 |
Brain Chemistry | 3 | 1.0 |
Models, Biological | 2 | 0.0 |
Binding Sites | 12 | 0.0 |
CHO Cells | 9 | 0.0 |
Cattle | 5 | 0.0 |
Hamsters | 12 | 0.0 |
Protein Conformation | 7 | 0.0 |
Receptors, Vasopressin/*agonists/genetics/metabolism | 2 | 100.0 |
Transfection | 17 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Hyponatremia/*metabolism | 2 | 100.0 |
Inappropriate ADH Syndrome/*metabolism | 2 | 100.0 |
Metallothionein/genetics | 2 | 5.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Zinc/administration & dosage | 2 | 40.0 |
*Adaptation, Physiological | 3 | 5.0 |
Benzazepines/pharmacology | 3 | 27.0 |
Body Water/*metabolism | 13 | 56.0 |
Homeostasis | 6 | 1.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Sodium/metabolism | 16 | 11.0 |
Age Factors | 15 | 0.0 |
Analysis of Variance | 22 | 1.0 |
Area Under Curve | 3 | 0.0 |
Comparative Study | 131 | 0.0 |
Hypothalamo-Hypophyseal System/*drug effects/metabolism | 2 | 66.0 |
Pituitary-Adrenal System/*drug effects/metabolism | 2 | 100.0 |
*Sex Characteristics | 2 | 1.0 |
COS Cells | 5 | 0.0 |
Child | 67 | 0.0 |
Child, Preschool | 40 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Infant | 32 | 0.0 |
Point Mutation | 3 | 0.0 |
Argipressin/*antagonists & inhibitors | 3 | 100.0 |
Hypothalamus/*metabolism | 3 | 9.0 |
Oxytocin/*metabolism | 3 | 37.0 |
Vasopressins/*metabolism | 9 | 60.0 |
Mammals | 2 | 0.0 |
*Arginine | 2 | 7.0 |
Argipressin/metabolism | 17 | 80.0 |
Cell Line | 18 | 0.0 |
Mutagenesis | 2 | 0.0 |
Radioligand Assay | 8 | 1.0 |
Receptors, Vasopressin/*chemistry/genetics/metabolism | 2 | 100.0 |
Second Messenger Systems | 2 | 2.0 |
Structure-Activity Relationship | 10 | 0.0 |
Tritium | 2 | 0.0 |
Cells, Cultured | 27 | 0.0 |
Corticotropin/metabolism | 5 | 14.0 |
Hypothalamus/drug effects/metabolism | 2 | 18.0 |
Receptors, Vasopressin/*antagonists & inhibitors | 13 | 92.0 |
Drug Interactions | 10 | 0.0 |
Nifedipine/pharmacology | 4 | 10.0 |
Vasoconstriction/*drug effects/physiology | 2 | 25.0 |
Verapamil/pharmacology | 2 | 2.0 |
*Genes, Dominant | 6 | 2.0 |
Magnetic Resonance Imaging | 12 | 1.0 |
Mutation/*physiology | 2 | 1.0 |
Neurophysins/*genetics | 9 | 75.0 |
Pedigree | 23 | 0.0 |
Water Deprivation/physiology | 7 | 87.0 |
Acute Disease | 5 | 0.0 |
Adolescent | 107 | 0.0 |
Angiotensin II/*blood | 13 | 50.0 |
Gene Expression Regulation | 3 | 0.0 |
In Situ Hybridization | 6 | 0.0 |
Neurons/*metabolism | 3 | 1.0 |
Nitric-Oxide Synthase/genetics/metabolism | 2 | 9.0 |
Aldosterone/blood | 67 | 34.0 |
Blood/metabolism | 6 | 17.0 |
Hydrocortisone/*blood | 11 | 7.0 |
Infusions, Intravenous | 45 | 6.0 |
Renin/blood | 87 | 28.0 |
Saline Solution, Hypertonic/*pharmacology | 11 | 73.0 |
Diabetes Insipidus, Neurogenic/*genetics | 4 | 100.0 |
Microscopy, Confocal | 3 | 0.0 |
*Mutation | 12 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Argipressin/blood/secretion | 7 | 100.0 |
Blood | 16 | 8.0 |
Urine | 23 | 57.0 |
Circadian Rhythm/physiology | 5 | 8.0 |
Fibromyalgia/metabolism/*physiopathology | 2 | 100.0 |
Hydrocortisone/blood/urine | 3 | 25.0 |
Hypothalamo-Hypophyseal System/metabolism/*physiopathology | 2 | 100.0 |
Pituitary-Adrenal System/metabolism/physiopathology | 2 | 66.0 |
Serotonin/metabolism | 2 | 2.0 |
Vasopressins/metabolism | 5 | 29.0 |
Blood Volume/drug effects | 7 | 58.0 |
Estradiol/blood | 5 | 0.0 |
Hydrocortisone/blood | 54 | 13.0 |
Thirst/drug effects | 2 | 100.0 |
Water-Electrolyte Balance/*drug effects | 9 | 56.0 |
Stereoisomerism | 2 | 0.0 |
Argipressin/*secretion | 37 | 100.0 |
Hypernatremia/*etiology | 2 | 100.0 |
*Thirst | 9 | 100.0 |
Heterozygote | 4 | 0.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
*Mutation, Missense | 6 | 1.0 |
Pituitary Gland, Posterior/*pathology | 2 | 66.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Polyuria | 2 | 100.0 |
Sequence Analysis, DNA | 11 | 0.0 |
Thirst | 9 | 81.0 |
Pituitary Gland/pathology | 2 | 8.0 |
Reference Values | 56 | 1.0 |
Angiotensin II/*pharmacology | 9 | 8.0 |
Diagnosis, Differential | 3 | 0.0 |
Hyperplasia | 3 | 0.0 |
Posture | 26 | 26.0 |
Receptor, Angiotensin, Type 1 | 2 | 1.0 |
Receptors, Angiotensin/physiology | 2 | 13.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Blood Volume/drug effects/physiology | 2 | 50.0 |
Hemodynamic Processes/drug effects/physiology | 2 | 8.0 |
Hemoglobins/metabolism | 3 | 1.0 |
Kidney/*metabolism | 10 | 5.0 |
Sex Characteristics | 8 | 1.0 |
Sodium/*metabolism | 6 | 9.0 |
Atrial Natriuretic Factor/blood | 41 | 49.0 |
Diuretics/administration & dosage/*pharmacology | 2 | 50.0 |
Epinephrine/blood | 18 | 14.0 |
*Exercise | 2 | 1.0 |
Hormones/*blood | 19 | 13.0 |
Norepinephrine/blood | 41 | 20.0 |
Oxygen Consumption | 7 | 2.0 |
Plasma Volume/*drug effects | 3 | 33.0 |
*Water-Electrolyte Balance | 30 | 71.0 |
Arteries/*physiology | 2 | 18.0 |
Posture/physiology | 2 | 11.0 |
*Pulse | 2 | 13.0 |
*Respiratory Physiology | 2 | 12.0 |
Exercise/*physiology | 15 | 3.0 |
Exercise Test | 8 | 3.0 |
Pituitary Gland/*physiopathology | 3 | 10.0 |
Smoking/*physiopathology | 2 | 20.0 |
Argipressin/physiology | 10 | 83.0 |
Case-Control Studies | 14 | 0.0 |
Linear Models | 2 | 0.0 |
Aldosterone/*urine | 4 | 66.0 |
Argipressin/urine | 5 | 83.0 |
Blood Pressure/physiology | 9 | 5.0 |
Body Mass Index | 4 | 0.0 |
Circadian Rhythm/*physiology | 8 | 8.0 |
Creatinine/urine | 15 | 13.0 |
Cyclic GMP/urine | 3 | 37.0 |
Diuresis/physiology | 4 | 57.0 |
Heart Rate/physiology | 9 | 9.0 |
Hydrocortisone/urine | 2 | 16.0 |
Sodium/*urine | 4 | 28.0 |
Stress/physiopathology | 2 | 8.0 |
Water-Electrolyte Balance/*physiology | 21 | 61.0 |
6-Ketoprostaglandin F1 alpha/urine | 2 | 50.0 |
Oxytocin/blood | 6 | 85.0 |
Postpartum Period | 5 | 6.0 |
Sodium/blood/urine | 4 | 57.0 |
Argipressin/administration & dosage/*pharmacology | 6 | 100.0 |
Cardiac Output/drug effects | 7 | 24.0 |
Heart Rate | 26 | 10.0 |
Vascular Resistance/drug effects | 10 | 15.0 |
Clinical Trials | 5 | 0.0 |
Age of Onset | 2 | 0.0 |
Cell Count | 3 | 0.0 |
Gene Expression | 4 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Desmopressin/pharmacology | 12 | 34.0 |
Dinoprostone/pharmacology | 3 | 3.0 |
Epinephrine/pharmacology | 2 | 2.0 |
Renal Agents/pharmacology | 4 | 50.0 |
Angiotensin-Converting Enzyme Inhibitors/therapeutic use | 4 | 2.0 |
Atrial Natriuretic Factor/physiology | 2 | 22.0 |
Renin-Angiotensin System/physiology | 3 | 6.0 |
Sympathetic Nervous System/physiology | 4 | 14.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Aquaporins/*metabolism | 4 | 12.0 |
Statistics, Nonparametric | 3 | 0.0 |
Cholecystokinin/*pharmacology | 2 | 8.0 |
Cross-Over Studies | 7 | 1.0 |
Double-Blind Method | 16 | 0.0 |
Peptides/*pharmacology | 3 | 1.0 |
Placebos | 7 | 2.0 |
Radioimmunoassay | 72 | 3.0 |
Time Factors | 72 | 0.0 |
Vasoconstrictor Agents/*pharmacology | 8 | 21.0 |
Chronic Disease | 14 | 0.0 |
Diuresis | 18 | 58.0 |
Hypothalamus/*physiopathology | 3 | 17.0 |
Water/diagnostic use | 4 | 66.0 |
Angiotensin II/blood | 22 | 38.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology | 2 | 2.0 |
Blood Volume/*physiology | 6 | 54.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Glomerular Filtration Rate/physiology | 3 | 15.0 |
Immersion | 6 | 33.0 |
Kidney/*physiopathology | 8 | 13.0 |
Natriuresis/*physiology | 4 | 57.0 |
Urine/chemistry | 7 | 30.0 |
Vasopressins/blood | 15 | 68.0 |
Creatinine/blood | 9 | 2.0 |
Potassium/blood | 22 | 25.0 |
Prospective Studies | 21 | 0.0 |
Serum Albumin/analysis | 2 | 1.0 |
Sodium/*blood | 4 | 19.0 |
Water-Electrolyte Balance/physiology | 13 | 38.0 |
Bradykinin/pharmacology | 3 | 6.0 |
Epithelial Cells | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Signal Transduction | 11 | 0.0 |
Blood Flow Velocity | 2 | 2.0 |
Hematocrit | 25 | 6.0 |
Thyrotropin/blood | 4 | 1.0 |
Thyroxine/blood | 3 | 1.0 |
Administration, Oral | 15 | 1.0 |
Hypertension/drug therapy | 2 | 3.0 |
Hypotension, Orthostatic/*physiopathology | 3 | 75.0 |
*Plasma Volume | 3 | 42.0 |
Sex Factors | 8 | 0.0 |
Corticotropin/*metabolism | 2 | 14.0 |
Tumor Cells, Cultured | 17 | 0.0 |
Aging/*metabolism | 6 | 2.0 |
Diuresis/*physiology | 5 | 62.0 |
Hydrocortisone/therapeutic use | 4 | 22.0 |
Inappropriate ADH Syndrome/metabolism | 3 | 75.0 |
Kidney/metabolism | 6 | 1.0 |
Angiotensin II/metabolism | 3 | 7.0 |
Argipressin/metabolism/physiology | 3 | 100.0 |
Hemodynamic Processes/physiology | 3 | 5.0 |
Renin/metabolism | 4 | 33.0 |
Water Deprivation/*physiology | 7 | 100.0 |
Argipressin/*immunology | 2 | 100.0 |
Argipressin/*physiology | 24 | 100.0 |
Autonomic Nervous System/physiopathology | 4 | 14.0 |
Fluid Therapy | 6 | 28.0 |
Thirst/physiology | 8 | 100.0 |
Water/*metabolism | 12 | 25.0 |
Severity of Illness Index | 5 | 0.0 |
Atrial Natriuretic Factor/*metabolism | 4 | 30.0 |
Hyponatremia/complications/*metabolism | 2 | 100.0 |
Argipressin/immunology/*metabolism | 2 | 100.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cytoplasm/metabolism | 5 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Cloning, Molecular | 9 | 0.0 |
DNA Primers | 5 | 0.0 |
DNA, Complementary | 4 | 0.0 |
GTP-Binding Proteins/metabolism | 3 | 1.0 |
Ligands | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Receptors, Vasopressin/genetics/*metabolism | 4 | 100.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Administration, Intranasal | 6 | 7.0 |
Cardiac Output | 4 | 8.0 |
Desmopressin/therapeutic use | 5 | 16.0 |
Hemodynamic Processes | 13 | 6.0 |
Pituitary Function Tests | 2 | 6.0 |
Stroke Volume | 3 | 4.0 |
Genes, Dominant | 4 | 0.0 |
Infant, Newborn | 22 | 0.0 |
Mutation | 9 | 0.0 |
Infant, Premature | 5 | 4.0 |
Oxygen/blood | 7 | 6.0 |
Respiration, Artificial | 3 | 5.0 |
Urodynamics/drug effects | 6 | 66.0 |
Water-Electrolyte Balance/drug effects | 7 | 50.0 |
Immunohistochemistry | 17 | 0.0 |
Argipressin/administration & dosage/*therapeutic use | 2 | 100.0 |
Blood Coagulation/*drug effects | 2 | 1.0 |
Drug Combinations | 3 | 0.0 |
Hemofiltration | 2 | 18.0 |
Vasoconstrictor Agents/administration & dosage/*therapeutic use | 2 | 100.0 |
Argipressin/*blood/urine | 3 | 100.0 |
Energy Intake | 2 | 1.0 |
*Fluid Therapy | 5 | 41.0 |
Argipressin/*genetics | 10 | 90.0 |
Estrogen Antagonists/pharmacology | 2 | 2.0 |
Estrogen Receptor alpha | 3 | 1.0 |
Estrogen Receptor beta | 3 | 3.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Bicycling/*physiology | 2 | 11.0 |
Drinking Behavior | 3 | 60.0 |
Hyponatremia/blood/*etiology | 2 | 100.0 |
Running/*physiology | 2 | 5.0 |
Swimming/*physiology | 2 | 13.0 |
Water-Electrolyte Imbalance/*physiopathology | 2 | 100.0 |
Corticotropin-Releasing Hormone/*metabolism | 3 | 27.0 |
Hypothalamo-Hypophyseal System/drug effects/metabolism | 3 | 42.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Pituitary-Adrenal System/drug effects/metabolism | 2 | 50.0 |
Rats, Wistar | 14 | 1.0 |
omega-N-Methylarginine/pharmacology | 2 | 4.0 |
Sequence Deletion | 4 | 0.0 |
Sheep | 9 | 1.0 |
Calcium/metabolism | 11 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Neurons/metabolism | 2 | 0.0 |
Receptors, Estrogen/*biosynthesis | 2 | 8.0 |
Supraoptic Nucleus/*metabolism | 3 | 42.0 |
Tissue Fixation | 2 | 2.0 |
Argipressin/secretion | 14 | 100.0 |
Clonidine/*pharmacology | 2 | 8.0 |
Corticotropin/*secretion | 18 | 39.0 |
Veins | 3 | 5.0 |
Atrial Natriuretic Factor/metabolism | 4 | 36.0 |
Cyclic AMP/metabolism | 13 | 2.0 |
Kidney Function Tests | 8 | 6.0 |
Kidney Tubules/drug effects/*metabolism | 2 | 28.0 |
Gestational Age | 10 | 1.0 |
Creatinine/metabolism | 8 | 11.0 |
Drinking/*physiology | 6 | 100.0 |
Glomerular Filtration Rate | 13 | 11.0 |
Potassium/urine | 20 | 51.0 |
Sodium/urine | 27 | 43.0 |
Vasopressins/physiology | 2 | 20.0 |
Cross-Sectional Studies | 2 | 0.0 |
Saline Solution, Hypertonic | 16 | 94.0 |
Thirst/*physiology | 11 | 100.0 |
Vasopressins/*blood | 17 | 73.0 |
Mice | 17 | 0.0 |
Hydrocortisone/*secretion | 8 | 33.0 |
Blood Pressure/drug effects/physiology | 5 | 13.0 |
Water-Electrolyte Balance | 29 | 46.0 |
Benzazepines/*pharmacology | 4 | 26.0 |
Binding, Competitive | 9 | 0.0 |
Hemostatics/pharmacology | 2 | 8.0 |
Pyrrolidines/*pharmacology | 5 | 23.0 |
Blood Pressure | 52 | 8.0 |
Weight Loss | 2 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
Water/metabolism | 8 | 11.0 |
Argipressin/diagnostic use | 2 | 100.0 |
Corticotropin/blood/secretion | 2 | 50.0 |
Corticotropin-Releasing Hormone/diagnostic use | 6 | 50.0 |
Hydrocortisone/blood/secretion | 3 | 37.0 |
Obesity/blood/*physiopathology | 2 | 12.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Heart Catheterization | 3 | 4.0 |
Myocardium/cytology | 2 | 6.0 |
Rabbits | 15 | 0.0 |
Receptors, Vasopressin/*genetics/*physiology | 2 | 66.0 |
Ventricular Function, Left/drug effects | 2 | 9.0 |
Incidence | 2 | 0.0 |
Anesthesia, General | 2 | 11.0 |
Kidney Concentrating Ability/*drug effects | 2 | 100.0 |
*Diagnosis, Differential | 2 | 40.0 |
*Medicine, Chinese Traditional | 2 | 8.0 |
Questionnaires | 3 | 0.0 |
Biological Transport/physiology | 2 | 1.0 |
Chlorides/metabolism | 2 | 2.0 |
Kidney/*physiology | 6 | 14.0 |
Kidney Tubules/metabolism | 3 | 9.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism | 2 | 4.0 |
Hypothalamus/*physiology | 2 | 7.0 |
Kidney Concentrating Ability/*physiology | 2 | 40.0 |
Mannitol/pharmacology | 2 | 15.0 |
Saline Solution, Hypertonic/pharmacology | 13 | 72.0 |
Sodium Chloride/pharmacology | 7 | 8.0 |
Vasopressins/blood/*physiology | 3 | 75.0 |
Corticotropin/blood | 33 | 20.0 |
Pituitary-Adrenal System/*drug effects/physiopathology | 2 | 50.0 |
Kidney/physiology | 8 | 14.0 |
Urine/physiology | 4 | 40.0 |
Atrial Natriuretic Factor/*blood | 40 | 61.0 |
Follow-Up Studies | 5 | 0.0 |
Hospitalization | 2 | 1.0 |
Prognosis | 5 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Heart Rate/drug effects | 37 | 14.0 |
Platelet Aggregation/drug effects | 4 | 1.0 |
Treatment Outcome | 11 | 0.0 |
*Aging | 3 | 1.0 |
Argipressin/genetics/*metabolism | 3 | 60.0 |
Body Water/metabolism | 9 | 28.0 |
Disease Models, Animal | 2 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Corticotropin/secretion | 14 | 22.0 |
Prolactin/secretion | 3 | 2.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Vasopressins/*genetics | 4 | 66.0 |
Protein Structure, Secondary | 4 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Argipressin/*analogs & derivatives/pharmacology | 2 | 100.0 |
Vasoconstrictor Agents/pharmacology | 2 | 5.0 |
Enuresis/*physiopathology | 2 | 100.0 |
Polysomnography | 2 | 4.0 |
Sleep Stages/physiology | 2 | 11.0 |
Urodynamics/physiology | 3 | 60.0 |
Circadian Rhythm/drug effects/physiology | 2 | 40.0 |
Desmopressin/administration & dosage | 5 | 38.0 |
Enuresis/drug therapy/*physiopathology | 2 | 100.0 |
Kidney Concentrating Ability/drug effects/physiology | 2 | 66.0 |
Renal Agents/administration & dosage | 2 | 100.0 |
Urodynamics/drug effects/*physiology | 2 | 100.0 |
Circadian Rhythm/drug effects | 2 | 14.0 |
Enuresis/*classification/diagnosis/etiology/therapy | 2 | 100.0 |
Argipressin/*administration & dosage | 6 | 100.0 |
Vasoconstrictor Agents/*administration & dosage | 2 | 50.0 |
Vasodilation/*drug effects | 6 | 15.0 |
Apoptosis | 3 | 0.0 |
Gene Deletion | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Neurophysins/genetics | 3 | 50.0 |
Argipressin/*blood/secretion | 11 | 91.0 |
Argipressin/antagonists & inhibitors/blood/*secretion | 2 | 100.0 |
Saline Solution, Hypertonic/therapeutic use | 2 | 100.0 |
Water Deprivation | 12 | 75.0 |
Hypotension, Orthostatic | 2 | 50.0 |
Tilt-Table Test | 2 | 28.0 |
Urodynamics | 2 | 25.0 |
Circadian Rhythm | 13 | 5.0 |
Arginine/analogs & derivatives/pharmacology | 3 | 10.0 |
Corticotropin-Releasing Hormone/secretion | 3 | 75.0 |
Hypothalamus/*drug effects/secretion | 4 | 57.0 |
Argipressin/*genetics/metabolism | 3 | 100.0 |
Diabetes Insipidus/*genetics | 7 | 50.0 |
Genotype | 2 | 0.0 |
Vasopressins/*genetics/metabolism | 2 | 100.0 |
Ethanol/*pharmacology | 6 | 5.0 |
Hypothalamo-Hypophyseal System/physiology | 4 | 13.0 |
Pituitary-Adrenal System/physiology | 4 | 23.0 |
Blotting, Northern | 4 | 0.0 |
Lower Body Negative Pressure | 3 | 25.0 |
Posture/*physiology | 6 | 20.0 |
Vasopressins/*secretion | 6 | 54.0 |
Corticotropin-Releasing Hormone/pharmacology | 5 | 14.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Hydrocortisone/secretion | 7 | 29.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Pituitary Gland/*drug effects/secretion | 2 | 22.0 |
Argipressin/blood/physiology | 2 | 100.0 |
*Circadian Rhythm | 5 | 2.0 |
Desmopressin/*therapeutic use | 5 | 16.0 |
Renal Agents/*therapeutic use | 2 | 40.0 |
Argipressin/genetics/physiology | 2 | 100.0 |
Diabetes Insipidus/*genetics/metabolism | 2 | 100.0 |
Oxytocin/metabolism | 5 | 55.0 |
Blotting, Western | 3 | 0.0 |
Hypothalamo-Hypophyseal System/drug effects/*metabolism | 2 | 33.0 |
Neuropeptides/pharmacology | 2 | 6.0 |
Pituitary Gland/*metabolism | 2 | 5.0 |
Infant, Premature/*physiology | 2 | 16.0 |
Positive-Pressure Respiration | 2 | 12.0 |
Brain/*metabolism | 4 | 0.0 |
Iodine Radioisotopes | 3 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Plasma Volume | 8 | 24.0 |
Retrospective Studies | 4 | 0.0 |
Uric Acid/blood | 2 | 3.0 |
Biological Markers/blood | 3 | 0.0 |
Endocrine Glands/*drug effects | 2 | 25.0 |
Hemodynamic Processes/drug effects | 14 | 8.0 |
Norepinephrine/administration & dosage | 2 | 50.0 |
Prolactin/blood | 12 | 2.0 |
Sodium Chloride/therapeutic use | 2 | 66.0 |
Corticotropin-Releasing Hormone/blood | 6 | 37.0 |
Pituitary-Adrenal System/*drug effects | 4 | 25.0 |
Psychiatric Status Rating Scales | 8 | 3.0 |
*Blood Pressure/drug effects | 4 | 33.0 |
Diuretics/therapeutic use | 2 | 3.0 |
Hypertension/*blood/drug therapy | 2 | 13.0 |
Vasopressins/*physiology | 11 | 61.0 |
Antihypertensive Agents/pharmacology | 2 | 4.0 |
Losartan/pharmacology | 2 | 6.0 |
Interleukin-1/*pharmacology | 6 | 1.0 |
Receptors, Vasopressin/physiology | 3 | 100.0 |
Recombinant Proteins | 4 | 0.0 |
*Acid-Base Equilibrium | 2 | 13.0 |
Carbon Dioxide/blood | 2 | 5.0 |
Exercise | 2 | 1.0 |
Pregnancy/*physiology | 4 | 9.0 |
Adenylate Cyclase/metabolism | 6 | 4.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Intracellular Membranes/metabolism | 3 | 1.0 |
Receptors, Vasopressin/*genetics/metabolism | 3 | 100.0 |
*Menstrual Cycle | 2 | 3.0 |
Pregnancy | 30 | 0.0 |
Receptors, Vasopressin/*metabolism | 4 | 100.0 |
Aquaporins/physiology | 3 | 75.0 |
Heart Failure, Congestive/*physiopathology | 5 | 25.0 |
Kidney/physiopathology | 7 | 11.0 |
Sympathetic Nervous System/physiopathology | 2 | 8.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
Pituitary Gland, Posterior/*physiology | 2 | 66.0 |
Receptors, Vasopressin/*chemistry/*metabolism | 2 | 100.0 |
X Chromosome | 4 | 0.0 |
Hepatorenal Syndrome/*blood | 2 | 66.0 |
Immunologic Techniques | 2 | 0.0 |
Kidney Tubules, Collecting/*metabolism | 2 | 33.0 |
Tissue Distribution | 6 | 0.0 |
*Drinking | 6 | 54.0 |
Renal Agents/therapeutic use | 2 | 66.0 |
Argipressin/*blood/immunology | 4 | 100.0 |
Blood Specimen Collection | 2 | 4.0 |
Calibration | 2 | 1.0 |
Centrifugation | 2 | 2.0 |
Immune Sera | 7 | 2.0 |
Platelet Count | 2 | 0.0 |
Blood Pressure/*physiology | 8 | 8.0 |
Body Fluids/*metabolism | 5 | 23.0 |
Hypertension/etiology | 2 | 4.0 |
Kidney Tubules/*metabolism | 2 | 12.0 |
Argipressin/blood/urine | 2 | 100.0 |
Blood Urea Nitrogen | 4 | 6.0 |
Diuretics/*pharmacology | 3 | 60.0 |
Argipressin/cerebrospinal fluid | 4 | 100.0 |
Oxytocin/*cerebrospinal fluid | 2 | 100.0 |
Corticotropin/blood/diagnostic use | 2 | 50.0 |
Drug Administration Schedule | 6 | 0.0 |
Insulin/diagnostic use | 6 | 12.0 |
Receptors, Oxytocin/genetics | 2 | 50.0 |
Histamine/pharmacology | 2 | 3.0 |
Pituitary Gland, Posterior/*secretion | 6 | 100.0 |
Water/administration & dosage/metabolism | 2 | 100.0 |
Argipressin/genetics | 2 | 66.0 |
Diabetes Insipidus, Nephrogenic/*genetics/metabolism | 3 | 37.0 |
Protein Binding | 4 | 0.0 |
Argipressin/blood/pharmacology | 3 | 100.0 |
Hypertension/*metabolism | 2 | 6.0 |
Pulsatile Flow | 2 | 4.0 |
Renin-Angiotensin System/*physiology | 4 | 7.0 |
Argipressin/blood/*secretion | 35 | 100.0 |
Hyponatremia/*etiology | 3 | 100.0 |
Inappropriate ADH Syndrome/*etiology | 4 | 100.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Corticotropin-Releasing Hormone/*diagnostic use | 7 | 53.0 |
Stimulation, Chemical | 12 | 2.0 |
Catecholamines/blood | 13 | 26.0 |
Osmotic Pressure | 6 | 9.0 |
Receptors, Vasopressin/antagonists & inhibitors | 8 | 100.0 |
Dexamethasone/*diagnostic use | 3 | 23.0 |
Feedback | 3 | 1.0 |
Alzheimer Disease/*metabolism | 4 | 1.0 |
Corticotropin-Releasing Hormone/*blood | 7 | 46.0 |
Oxygen Consumption/physiology | 4 | 5.0 |
Sports | 3 | 23.0 |
Enzyme Activation | 4 | 0.0 |
Peptides/pharmacology | 4 | 2.0 |
Blood Glucose/analysis | 9 | 1.0 |
Desmopressin/*pharmacology | 9 | 26.0 |
Glucagon/blood | 2 | 2.0 |
Insulin/blood | 6 | 0.0 |
Atrial Natriuretic Factor/*secretion | 4 | 100.0 |
Adenosine Triphosphate/*pharmacology | 3 | 11.0 |
Calcium/*metabolism | 9 | 1.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Rats, Inbred WKY | 3 | 4.0 |
Adrenal Cortex/drug effects/*physiology | 2 | 100.0 |
*Homeostasis | 3 | 5.0 |
Receptors, Vasopressin/metabolism | 5 | 71.0 |
Exertion/*physiology | 2 | 3.0 |
Desmopressin/*administration & dosage | 3 | 25.0 |
Dinoprostone/urine | 4 | 50.0 |
Recurrence | 4 | 0.0 |
Hypoglycemia/*physiopathology | 5 | 55.0 |
Oxytocin/*secretion | 5 | 83.0 |
Receptors, Serotonin/*physiology | 2 | 25.0 |
Depression/*physiopathology | 2 | 40.0 |
Sleep/physiology | 2 | 8.0 |
Wakefulness/physiology | 2 | 13.0 |
Pituitary Gland, Posterior/*physiopathology | 2 | 100.0 |
Calcium Channel Blockers/pharmacology | 3 | 3.0 |
Electric Stimulation | 4 | 1.0 |
Norepinephrine/pharmacology | 8 | 10.0 |
Potassium Chloride/pharmacology | 2 | 3.0 |
Hormones/*physiology | 2 | 4.0 |
Natriuresis/physiology | 2 | 66.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Kidney Medulla/*metabolism | 2 | 50.0 |
Heart Rate/*drug effects | 3 | 10.0 |
Serum Albumin/therapeutic use | 2 | 40.0 |
Aldosterone/blood/secretion | 2 | 50.0 |
Kidney Failure, Chronic/*blood | 5 | 7.0 |
*Renal Dialysis | 10 | 2.0 |
Indoles/*pharmacology | 4 | 4.0 |
Uterus/*blood supply | 3 | 12.0 |
Vasoconstriction/*drug effects | 3 | 8.0 |
Phosphorylation | 6 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Regression Analysis | 17 | 1.0 |
Body Weight | 4 | 0.0 |
Dehydration/*physiopathology | 2 | 40.0 |
Drinking | 12 | 52.0 |
Infusions, Parenteral | 7 | 4.0 |
Aldosterone/*blood | 18 | 38.0 |
Antihypertensive Agents/*pharmacology | 2 | 4.0 |
Glomerular Filtration Rate/drug effects | 10 | 20.0 |
Kidney Tubules/*drug effects/physiology | 2 | 100.0 |
Renal Circulation/*drug effects | 6 | 25.0 |
Chromatography, High Pressure Liquid | 17 | 1.0 |
Peptides/*secretion | 2 | 15.0 |
Swine | 2 | 0.0 |
Vasopressins/pharmacology | 2 | 12.0 |
*Altitude | 6 | 10.0 |
*Aquaporins | 5 | 6.0 |
Argipressin/blood/*pharmacology | 6 | 100.0 |
Body Water/*physiology | 2 | 28.0 |
Drug Resistance | 4 | 0.0 |
Kidney/*drug effects | 7 | 29.0 |
Arginine/metabolism | 2 | 3.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Vasopressins/*pharmacology | 4 | 44.0 |
Secretory Rate/drug effects | 3 | 3.0 |
Furosemide/*administration & dosage | 2 | 66.0 |
Potassium/metabolism/urine | 2 | 100.0 |
Sodium/metabolism/urine | 3 | 60.0 |
Desmopressin/blood | 2 | 100.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Plasma/chemistry | 2 | 6.0 |
Carcinoma, Small Cell/*metabolism | 3 | 13.0 |
Lung Neoplasms/*metabolism | 4 | 5.0 |
Protein Precursors/*genetics | 3 | 2.0 |
Protein Sorting Signals/*genetics | 2 | 5.0 |
Adrenal Glands/physiology | 2 | 13.0 |
Dehydration/blood/*physiopathology | 2 | 100.0 |
Plasma Volume/physiology | 3 | 30.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Dehydration | 3 | 75.0 |
Diet, Sodium-Restricted | 4 | 13.0 |
Syndrome | 6 | 0.0 |
Forearm | 3 | 12.0 |
Injections, Intra-Arterial | 2 | 5.0 |
Radial Artery/drug effects/physiology | 2 | 100.0 |
Regional Blood Flow/drug effects | 12 | 11.0 |
Skin/blood supply | 3 | 4.0 |
Kidney Failure, Chronic/*physiopathology | 2 | 13.0 |
DNA/chemistry | 2 | 0.0 |
Aging/*physiology | 7 | 2.0 |
Corticotropin-Releasing Hormone/metabolism | 2 | 22.0 |
Neuropeptides/*metabolism | 2 | 2.0 |
Hypothalamo-Hypophyseal System/physiopathology | 3 | 8.0 |
Diabetes Insipidus/etiology | 2 | 50.0 |
Sodium, Dietary/administration & dosage | 2 | 22.0 |
Vasopressins/secretion | 3 | 75.0 |
Water/administration & dosage | 4 | 80.0 |
*Petrosal Sinus Sampling | 4 | 57.0 |
Ion Channels/*urine | 2 | 100.0 |
Adrenalectomy | 5 | 10.0 |
Natriuresis | 7 | 46.0 |
Postoperative Period | 5 | 1.0 |
Cyclic AMP/urine | 4 | 25.0 |
Natriuretic Peptide, Brain | 3 | 14.0 |
Argipressin/*diagnostic use | 5 | 100.0 |
Dexamethasone/diagnostic use | 2 | 5.0 |
Receptors, Vasopressin/*physiology | 2 | 40.0 |
Central Venous Pressure | 2 | 50.0 |
*Hemodynamic Processes | 4 | 8.0 |
Hemoglobins/analysis | 5 | 1.0 |
Pressure | 5 | 3.0 |
Saline Solution, Hypertonic/diagnostic use | 6 | 85.0 |
Dexamethasone/pharmacology | 6 | 1.0 |
Endocrine Glands/physiology | 3 | 25.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Hypothalamo-Hypophyseal System/*physiology | 3 | 12.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
Electrophysiology | 3 | 0.0 |
Fura-2/metabolism | 2 | 22.0 |
Hormone Antagonists/pharmacology | 4 | 6.0 |
Oxytocin/*pharmacology | 2 | 11.0 |
Potassium/metabolism | 5 | 4.0 |
Dopamine/*administration & dosage | 2 | 33.0 |
Lithium/diagnostic use | 2 | 66.0 |
Natriuresis/*drug effects | 7 | 77.0 |
Renal Circulation | 3 | 8.0 |
Urination | 4 | 44.0 |
Metabolic Clearance Rate | 8 | 2.0 |
Guanylate Cyclase/metabolism | 2 | 10.0 |
Diuretics/*therapeutic use | 2 | 11.0 |
Diabetes Mellitus, Type 1/*metabolism | 3 | 5.0 |
Growth Hormone/secretion | 3 | 3.0 |
Pituitary Hormones/*secretion | 4 | 40.0 |
Argipressin/blood/*metabolism/urine | 3 | 100.0 |
Blood Platelets/*metabolism | 9 | 3.0 |
*Diet, Sodium-Restricted | 3 | 20.0 |
Neurophysins/blood | 3 | 100.0 |
Pregnancy Trimester, Third | 4 | 2.0 |
Hypothalamo-Hypophyseal System/*drug effects | 2 | 10.0 |
Single-Blind Method | 7 | 3.0 |
Metoclopramide/*diagnostic use | 2 | 11.0 |
Parathyroid Hormone/blood | 5 | 3.0 |
Plethysmography | 3 | 9.0 |
Sympathetic Nervous System/*drug effects | 3 | 20.0 |
Arousal/*physiology | 2 | 6.0 |
Forearm/blood supply | 7 | 14.0 |
Hemodynamic Processes/*drug effects | 18 | 16.0 |
Infusions, Intra-Arterial | 2 | 3.0 |
Argipressin/antagonists & inhibitors/pharmacology | 2 | 100.0 |
Autoradiography | 4 | 0.0 |
Furosemide/pharmacology | 3 | 20.0 |
Kidney/drug effects | 2 | 4.0 |
Molecular Structure | 2 | 0.0 |
Electrolytes/metabolism | 2 | 11.0 |
Plasma Volume/*physiology | 3 | 27.0 |
Heart Transplantation/*physiology | 2 | 9.0 |
*Lower Body Negative Pressure | 3 | 50.0 |
Flow Cytometry | 4 | 0.0 |
Hypoglycemia/*metabolism | 5 | 41.0 |
Insulin/*pharmacology | 6 | 2.0 |
Valproic Acid/pharmacology | 2 | 18.0 |
Corticosterone/blood | 2 | 5.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Interleukin-1/administration & dosage/*pharmacology | 2 | 16.0 |
Recombinant Proteins/administration & dosage/pharmacology | 2 | 3.0 |
Amino Acids/metabolism | 2 | 2.0 |
Glucose/metabolism | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Argipressin/blood/*urine | 4 | 100.0 |
Corticotropin-Releasing Hormone/*pharmacology | 10 | 41.0 |
Hypothalamo-Hypophyseal System/drug effects | 2 | 11.0 |
Baroreflex/*physiology | 2 | 40.0 |
Cardiovascular Physiology | 5 | 25.0 |
Extracellular Space/*physiology | 2 | 18.0 |
*Space Flight | 2 | 6.0 |
Luteinizing Hormone/blood | 3 | 0.0 |
Atrial Natriuretic Factor/blood/metabolism | 2 | 66.0 |
Renin/blood/metabolism | 2 | 66.0 |
Cyclic GMP/blood | 3 | 21.0 |
Endothelins/blood | 2 | 14.0 |
Calcium/*blood | 3 | 3.0 |
Drug Synergism | 7 | 0.0 |
Polyuria/etiology | 2 | 100.0 |
Argipressin/therapeutic use | 2 | 100.0 |
Estradiol/pharmacology | 2 | 0.0 |
Serotonin/*physiology | 2 | 7.0 |
Renin/*blood | 19 | 20.0 |
Corticotropin/blood/*secretion | 12 | 52.0 |
Japan | 3 | 0.0 |
Vasopressins/*cerebrospinal fluid | 3 | 75.0 |
Cell Membrane/metabolism | 11 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Amniotic Fluid/*metabolism | 2 | 5.0 |
Fetus/*metabolism | 2 | 2.0 |
Corticotropin-Releasing Hormone/physiology | 3 | 42.0 |
Corticotropin-Releasing Hormone/*administration & dosage | 2 | 50.0 |
Diabetes Insipidus/*physiopathology | 2 | 100.0 |
Argipressin/analogs & derivatives/*pharmacology | 3 | 100.0 |
Adrenal Cortex/*metabolism | 2 | 12.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Stress/*metabolism | 2 | 11.0 |
Restriction Mapping | 4 | 0.0 |
Hyponatremia/blood/physiopathology | 2 | 100.0 |
Stroke Volume/drug effects | 4 | 13.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Hydrolysis | 4 | 0.0 |
Pregnancy/*blood | 3 | 1.0 |
Hormones/blood | 9 | 8.0 |
*Kidney Transplantation | 5 | 1.0 |
Lithium/urine | 2 | 40.0 |
Dopamine/blood | 2 | 8.0 |
Argipressin/*cerebrospinal fluid | 5 | 100.0 |
Adenosine Diphosphate/pharmacology | 2 | 1.0 |
Argipressin/analogs & derivatives/pharmacology | 3 | 100.0 |
Blood Platelets/drug effects/*metabolism | 3 | 4.0 |
Recombinant Proteins/pharmacology | 6 | 0.0 |
Hemodynamic Processes/*physiology | 2 | 6.0 |
Hypertension/etiology/physiopathology | 3 | 60.0 |
Anesthesia | 4 | 12.0 |
Diuresis/drug effects | 13 | 56.0 |
Electrolytes/*metabolism | 2 | 28.0 |
Kidney/drug effects/*metabolism | 2 | 18.0 |
Argipressin/*therapeutic use | 2 | 100.0 |
Cushing Syndrome/*etiology | 2 | 16.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 5 | 9.0 |
Naloxone/pharmacology | 9 | 19.0 |
Pituitary-Adrenal System/*physiopathology | 5 | 20.0 |
Insulin/pharmacology | 5 | 1.0 |
Metoclopramide/*pharmacology | 7 | 20.0 |
Receptors, Vasopressin/classification/*genetics/metabolism | 2 | 100.0 |
beta-Endorphin/blood | 6 | 17.0 |
Thirst/drug effects/*physiology | 2 | 100.0 |
Apomorphine/pharmacology | 3 | 13.0 |
Physostigmine/pharmacology | 3 | 18.0 |
Chlorides/urine | 2 | 66.0 |
Diuresis/*drug effects | 8 | 61.0 |
Rats, Brattleboro | 4 | 66.0 |
Urination/drug effects | 3 | 75.0 |
Carcinoma, Small Cell/blood/*secretion | 2 | 100.0 |
Hypotension, Orthostatic/blood/physiopathology | 2 | 100.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Argipressin/*urine | 13 | 100.0 |
Cerebral Hemorrhage/metabolism | 2 | 66.0 |
Pituitary-Adrenal System/physiopathology | 2 | 8.0 |
DNA/genetics | 3 | 0.0 |
Neuropsychological Tests | 2 | 0.0 |
Argipressin/metabolism/*secretion | 2 | 100.0 |
Diabetes Insipidus/physiopathology | 4 | 100.0 |
*Pregnancy | 3 | 2.0 |
Naloxone/*pharmacology | 8 | 28.0 |
Norepinephrine/*blood | 7 | 12.0 |
Parasympatholytics/pharmacology | 2 | 50.0 |
*Heat | 3 | 2.0 |
Sodium Chloride/*administration & dosage | 2 | 22.0 |
Water-Electrolyte Balance/drug effects/physiology | 3 | 42.0 |
Hypothalamo-Hypophyseal System/drug effects/*physiology | 3 | 30.0 |
Pituitary-Adrenal System/drug effects/*physiology | 2 | 50.0 |
Saline Solution, Hypertonic/*diagnostic use | 2 | 100.0 |
Water-Electrolyte Balance/drug effects/*physiology | 2 | 66.0 |
Administration, Inhalation | 2 | 1.0 |
Baroreflex/drug effects | 2 | 66.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Drinking Behavior/*physiology | 2 | 100.0 |
Molecular Weight | 2 | 0.0 |
Oxytocin/pharmacology | 5 | 45.0 |
Brain/*physiology | 3 | 2.0 |
Endorphins/*physiology | 5 | 31.0 |
*Physical Education and Training | 2 | 3.0 |
Argipressin/analysis | 3 | 50.0 |
Oxytocin/analysis | 2 | 50.0 |
Atrial Natriuretic Factor/*pharmacology | 8 | 33.0 |
Corticotropin-Releasing Hormone/*antagonists & inhibitors/pharmacology | 3 | 75.0 |
Steroids/*metabolism | 2 | 5.0 |
Inositol Phosphates/metabolism | 3 | 2.0 |
Arginine/blood | 2 | 28.0 |
Neuropeptide Y/blood | 4 | 17.0 |
Combined Modality Therapy | 2 | 0.0 |
Glomerulonephritis/*physiopathology | 2 | 40.0 |
Indomethacin/*pharmacology | 5 | 12.0 |
Natriuresis/drug effects | 9 | 33.0 |
Pituitary Gland/drug effects/*physiology | 2 | 25.0 |
Sleep/*physiology | 2 | 3.0 |
Body Temperature/physiology | 2 | 8.0 |
Body Temperature | 5 | 5.0 |
Electrocardiography | 3 | 0.0 |
*Immersion | 3 | 60.0 |
Temperature | 2 | 0.0 |
Water | 3 | 5.0 |
NG-Nitroarginine Methyl Ester | 2 | 18.0 |
Nitric-Oxide Synthase | 2 | 5.0 |
Cardiovascular System/*drug effects | 2 | 25.0 |
*Gene Expression | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Lactates/blood | 5 | 6.0 |
Lactic Acid | 3 | 4.0 |
Cross Reactions | 4 | 0.0 |
Diabetes Insipidus/*drug therapy | 2 | 66.0 |
Gastrin-Releasing Peptide | 2 | 2.0 |
Argipressin/*blood/pharmacology | 2 | 100.0 |
Phenylephrine/pharmacology | 2 | 5.0 |
Blood Pressure/*drug effects | 13 | 8.0 |
Body Temperature Regulation/*drug effects | 4 | 28.0 |
Indomethacin/pharmacology | 5 | 2.0 |
Pressoreceptors/*physiology | 4 | 33.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
*Anesthesia, General | 2 | 9.0 |
*Anesthesia, Epidural | 2 | 18.0 |
*Renin-Angiotensin System/drug effects | 2 | 33.0 |
Captopril/therapeutic use | 2 | 10.0 |
*Positive-Pressure Respiration | 2 | 18.0 |
Sympathetic Nervous System/*physiology | 3 | 6.0 |
Captopril/*pharmacology | 2 | 5.0 |
*Nephrectomy | 2 | 11.0 |
Renin-Angiotensin System/*drug effects | 5 | 3.0 |
Arachidonic Acid/metabolism | 2 | 2.0 |
Denervation | 2 | 5.0 |
Dogs | 12 | 1.0 |
Liver/metabolism | 2 | 0.0 |
Autoantibodies/*blood | 2 | 0.0 |
Diabetes Insipidus/*metabolism | 3 | 75.0 |
Hydrocortisone/blood/*secretion | 3 | 30.0 |
Arteries/drug effects | 3 | 25.0 |
Muscle Contraction/drug effects | 4 | 4.0 |
Muscle, Smooth, Vascular/*drug effects | 2 | 10.0 |
Piperidines/pharmacology | 2 | 3.0 |
Quinolones/pharmacology | 2 | 18.0 |
Neuropeptides/*blood | 4 | 22.0 |
Kidney/*drug effects/metabolism | 2 | 18.0 |
Water/*diagnostic use | 3 | 75.0 |
Renin-Angiotensin System | 7 | 33.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Renal Dialysis | 7 | 2.0 |
Saline Solution, Hypertonic/administration & dosage | 4 | 80.0 |
Muscle, Smooth, Vascular/drug effects | 2 | 8.0 |
Parathyroid Hormone/*pharmacology | 2 | 6.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Teriparatide | 2 | 12.0 |
Fluorescent Dyes | 2 | 0.0 |
Argipressin/*analysis | 8 | 88.0 |
Aging/*blood | 2 | 2.0 |
Lipotropin/secretion | 2 | 100.0 |
Argipressin/blood/*physiology | 5 | 100.0 |
Cold | 2 | 1.0 |
Hypertension/*physiopathology | 9 | 14.0 |
Valsalva Maneuver | 2 | 25.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Evaluation Studies | 3 | 0.0 |
*Water Deprivation | 2 | 100.0 |
Factor VIII/analysis | 4 | 3.0 |
Fibrinolysis/*drug effects | 2 | 3.0 |
von Willebrand Factor/analysis | 2 | 0.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Corticotropin/*physiology | 2 | 22.0 |
Pituitary Gland, Posterior/physiology | 3 | 100.0 |
Pituitary Hormones, Posterior/*physiology | 2 | 100.0 |
Hormones/*metabolism | 2 | 8.0 |
Kidney Concentrating Ability | 8 | 72.0 |
Argipressin/antagonists & inhibitors | 2 | 100.0 |
Blood Volume | 14 | 28.0 |
Physical Fitness/*physiology | 2 | 5.0 |
Nicotine/*pharmacology | 3 | 11.0 |
Oxytocin/*blood | 11 | 68.0 |
gamma-Aminobutyric Acid/*physiology | 2 | 13.0 |
Cyclic GMP/*metabolism | 2 | 5.0 |
Catecholamines/*blood | 3 | 9.0 |
Vasopressins/antagonists & inhibitors | 2 | 100.0 |
Blood Platelets/*drug effects/metabolism | 2 | 5.0 |
Cystinyl Aminopeptidase/blood | 2 | 66.0 |
Kidney Concentrating Ability/physiology | 4 | 50.0 |
*Blood Pressure | 11 | 9.0 |
Exertion | 2 | 2.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
*Body Weight | 2 | 3.0 |
Bulimia/*blood | 2 | 22.0 |
Blood Volume/*drug effects | 2 | 66.0 |
Central Venous Pressure/drug effects | 2 | 50.0 |
Glucose/pharmacology | 2 | 1.0 |
*Cardiovascular Physiology | 3 | 11.0 |
Inappropriate ADH Syndrome/physiopathology | 3 | 100.0 |
Hypothalamus/physiopathology | 3 | 18.0 |
Neurotransmitters/*physiology | 4 | 12.0 |
Renin-Angiotensin System/*drug effects/physiology | 2 | 13.0 |
*Schizophrenic Psychology | 2 | 3.0 |
Cystinyl Aminopeptidase/*blood | 2 | 50.0 |
Bradykinin/*pharmacology | 2 | 5.0 |
Phosphatidylinositols/*metabolism | 2 | 2.0 |
Ultrafiltration | 3 | 5.0 |
Homeostasis/*physiology | 2 | 4.0 |
Receptors, Angiotensin/*analysis/drug effects | 2 | 100.0 |
*Receptors, Vasopressin | 5 | 100.0 |
Argipressin/*blood/*urine | 2 | 100.0 |
Kidney Failure, Chronic/*blood/physiopathology/therapy | 2 | 40.0 |
Memory/*physiology | 2 | 3.0 |
Stress/*physiopathology | 5 | 16.0 |
Calcium/physiology | 3 | 1.0 |
Potassium/pharmacology | 2 | 3.0 |
Orchiectomy | 2 | 1.0 |
Vasopressins/*antagonists & inhibitors | 3 | 100.0 |
beta-Endorphin/*blood | 2 | 14.0 |
Carcinoma, Squamous Cell/*complications | 2 | 40.0 |
Bicycling | 2 | 15.0 |
*Cold | 2 | 3.0 |
Kidney Transplantation/*physiology | 3 | 6.0 |
Receptors, Opioid/*drug effects | 3 | 60.0 |
Oxytocin/*urine | 2 | 100.0 |
*Gravitation | 2 | 20.0 |
*Posture | 7 | 31.0 |
Reflex/*physiology | 3 | 13.0 |
Biological Transport | 2 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Hypoglycemia/*blood | 4 | 30.0 |
Insulin | 4 | 26.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Receptors, Vasopressin | 15 | 65.0 |
Pituitary Gland, Posterior/*metabolism | 3 | 100.0 |
Fever/*physiopathology | 2 | 18.0 |
Plasma Volume/drug effects | 2 | 33.0 |
Culture Media | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Alcoholism/*physiopathology | 2 | 22.0 |
Epinephrine/*blood | 5 | 17.0 |
Thirst/*drug effects/physiology | 2 | 100.0 |
Oxytocin/secretion | 2 | 100.0 |
Pituitary Gland/drug effects/*secretion | 3 | 25.0 |
Pituitary Gland, Posterior/drug effects/*secretion | 3 | 100.0 |
Drinking/physiology | 2 | 33.0 |
Receptors, Angiotensin/*metabolism | 2 | 12.0 |
Fetus/*physiology | 4 | 10.0 |
Electroencephalography | 2 | 0.0 |
Electromyography | 2 | 1.0 |
Calcitonin/pharmacology | 3 | 13.0 |
Glucagon/pharmacology | 2 | 6.0 |
Rats, Inbred Strains | 19 | 2.0 |
*Smoking | 2 | 2.0 |
Oxytocin/blood/*secretion | 7 | 77.0 |
Body Temperature Regulation/*physiology | 4 | 17.0 |
Exercise/physiology | 2 | 3.0 |
Physical Endurance | 2 | 6.0 |
*Running | 2 | 7.0 |
Water/*administration & dosage | 2 | 66.0 |
Receptors, Angiotensin/drug effects | 3 | 50.0 |
*Relaxation Techniques | 2 | 18.0 |
Piperazines/*pharmacology | 2 | 3.0 |
Biological Transport/drug effects | 3 | 1.0 |
Diabetes Mellitus, Type 1/*blood/physiopathology | 2 | 10.0 |
Galanin | 3 | 7.0 |
Polyuria/*etiology | 2 | 100.0 |
Lypressin/pharmacology | 5 | 62.0 |
*Electroconvulsive Therapy | 2 | 11.0 |
Argipressin/*analysis/pharmacology | 2 | 100.0 |
Isometric Contraction | 2 | 11.0 |
Heart Failure, Congestive/*drug therapy | 3 | 5.0 |
*Kidney Function Tests | 2 | 16.0 |
Kidney Tubules/*physiology | 2 | 28.0 |
Behavior, Animal/*drug effects | 3 | 13.0 |
Testosterone/blood | 3 | 0.0 |
Trimethaphan/pharmacology | 3 | 100.0 |
Sodium Chloride/diagnostic use | 5 | 55.0 |
Protirelin/diagnostic use | 2 | 1.0 |
Lymphatic Metastasis | 2 | 0.0 |
Renin-Angiotensin System/drug effects | 4 | 6.0 |
Reproducibility of Results | 2 | 0.0 |
Kidney Failure, Chronic/blood/*physiopathology | 3 | 50.0 |
*Blood Volume | 8 | 47.0 |
*Exertion | 13 | 8.0 |
Hormones/blood/*physiology | 2 | 50.0 |
*Physical Fitness | 2 | 5.0 |
Tritium/diagnostic use | 2 | 1.0 |
Hormones/*pharmacology | 2 | 4.0 |
Monocytes/metabolism | 2 | 0.0 |
Hypoglycemia/chemically induced/*physiopathology | 3 | 37.0 |
Somatostatin/*pharmacology | 2 | 4.0 |
Insulin/*diagnostic use | 4 | 21.0 |
Pain/physiopathology | 2 | 9.0 |
Ipecac/*pharmacology | 2 | 100.0 |
Nausea/*blood/chemically induced | 3 | 100.0 |
Cyclic GMP/*blood | 2 | 33.0 |
Dinoprostone/*urine | 2 | 50.0 |
Hyponatremia/*blood | 2 | 100.0 |
Schizophrenia/*blood | 3 | 33.0 |
Water Intoxication/*blood | 2 | 100.0 |
Solubility | 2 | 0.0 |
Hypoglycemia/*blood/chemically induced | 4 | 50.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Immersion/*physiopathology | 5 | 45.0 |
Calcium/blood | 3 | 1.0 |
Saline Solution, Hypertonic/administration & dosage/*pharmacology | 2 | 100.0 |
Silicon Dioxide | 2 | 12.0 |
Adenoma/*metabolism | 2 | 3.0 |
Pituitary Neoplasms/*metabolism | 2 | 5.0 |
Vasopressins/blood/*secretion | 2 | 100.0 |
Apgar Score | 2 | 8.0 |
Argipressin/*biosynthesis | 2 | 66.0 |
Chromatography | 2 | 1.0 |
Neurophysins/*blood | 5 | 83.0 |
*Renin-Angiotensin System | 6 | 21.0 |
Hypoglycemia/chemically induced/*metabolism | 2 | 33.0 |
Chorionic Gonadotropin/pharmacology | 2 | 1.0 |
Pregnancy/*metabolism | 3 | 5.0 |
Receptors, Oxytocin | 2 | 28.0 |
Uterine Contraction/drug effects | 2 | 14.0 |
Inappropriate ADH Syndrome/blood | 3 | 100.0 |
Asthma/*urine | 2 | 66.0 |
Fluid Therapy/*adverse effects | 2 | 50.0 |
Hyponatremia/etiology | 4 | 66.0 |
Nifedipine/*pharmacology | 3 | 23.0 |
Heart Failure, Congestive/*blood | 2 | 13.0 |
*Diuresis | 4 | 80.0 |
Hypertonic Solutions/pharmacology | 2 | 18.0 |
Mannitol/*pharmacology | 2 | 40.0 |
Stress, Psychological/*physiopathology | 2 | 16.0 |
Receptors, Angiotensin/metabolism | 3 | 20.0 |
Furosemide/*pharmacology | 3 | 60.0 |
Brain/physiology | 3 | 4.0 |
Captopril/administration & dosage/*pharmacology | 2 | 28.0 |
Depression, Chemical | 2 | 1.0 |
Diabetic Neuropathies/blood/*physiopathology | 2 | 22.0 |
Dehydration/blood | 7 | 100.0 |
Receptors, Angiotensin/*physiology | 3 | 33.0 |
Nitroprusside/pharmacology | 3 | 4.0 |
Pressoreceptors/physiopathology | 2 | 28.0 |
Metergoline/pharmacology | 2 | 33.0 |
Blood Platelets/*analysis | 2 | 11.0 |
Receptors, Atrial Natriuretic Factor | 2 | 66.0 |
Argipressin/blood/*cerebrospinal fluid | 2 | 100.0 |
Yohimbine/*pharmacology | 2 | 50.0 |
Growth Hormone/blood | 7 | 2.0 |
Progesterone/blood | 2 | 0.0 |
Pregnancy, Animal/*physiology | 2 | 22.0 |
Prostaglandins/physiology | 2 | 11.0 |
Corticotropin/deficiency | 2 | 20.0 |
Diabetes Insipidus/*blood | 2 | 100.0 |
Rats, Inbred SHR | 2 | 2.0 |
Valproic Acid/*pharmacology | 2 | 10.0 |
Vascular Resistance/*drug effects | 2 | 15.0 |
Hyponatremia/blood | 2 | 100.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Pituitary Gland, Posterior/*drug effects/secretion | 2 | 100.0 |
Argipressin/*blood/metabolism | 2 | 100.0 |
Argipressin/blood/pharmacology/*urine | 2 | 100.0 |
Kallikreins/*urine | 2 | 22.0 |
Drug Tolerance | 2 | 1.0 |
Growth Hormone/*blood | 2 | 1.0 |
Propranolol/*pharmacology | 2 | 12.0 |
Blood-Brain Barrier | 3 | 5.0 |
Pseudotumor Cerebri/*cerebrospinal fluid | 2 | 100.0 |
Hypertension/*blood | 5 | 8.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Inappropriate ADH Syndrome/*urine | 2 | 100.0 |
Water Intoxication/*etiology | 2 | 100.0 |
Oxytocin/urine | 2 | 100.0 |
Pressoreceptors/drug effects/*physiology | 2 | 100.0 |
Electrolytes/blood | 4 | 28.0 |
Argipressin/pharmacology/physiology | 2 | 100.0 |
Blood Platelets/*enzymology | 2 | 2.0 |
Glomerulonephritis/*metabolism | 3 | 27.0 |
Prostaglandins E/urine | 4 | 80.0 |
Smoking/blood | 2 | 4.0 |
Water/pharmacology | 3 | 60.0 |
Factor VIII/*metabolism | 2 | 3.0 |
Dinoprost | 2 | 5.0 |
Dinoprostone | 9 | 13.0 |
Prostaglandins E/*urine | 3 | 42.0 |
Argipressin/administration & dosage/blood/*pharmacology | 4 | 100.0 |
*Surgical Procedures, Operative | 2 | 6.0 |
Diabetes Insipidus/blood | 10 | 90.0 |
Dehydration/*blood | 3 | 100.0 |
Hypernatremia/*blood | 2 | 100.0 |
Species Specificity | 3 | 0.0 |
Metoclopramide/pharmacology | 2 | 6.0 |
Vasotocin/*blood | 2 | 100.0 |
Argipressin/*blood/*cerebrospinal fluid | 2 | 100.0 |
Autonomic Nervous System/drug effects | 2 | 40.0 |
Cats | 3 | 0.0 |
Pressoreceptors/drug effects | 2 | 33.0 |
Chromatography, Gel | 3 | 0.0 |
Anoxia/*physiopathology | 3 | 7.0 |
Sodium Chloride/*pharmacology | 9 | 30.0 |
Cardiovascular System/drug effects | 2 | 66.0 |
Hemostasis/*drug effects | 3 | 4.0 |
Argipressin/blood/pharmacology/*secretion | 2 | 100.0 |
Argipressin/*blood/isolation & purification | 3 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors | 2 | 5.0 |
*Brain Chemistry | 2 | 1.0 |
Nephrectomy | 3 | 3.0 |
Histocytochemistry | 2 | 0.0 |
Diabetes Insipidus/*diagnosis | 2 | 100.0 |
Ovarian Follicle/*analysis | 2 | 28.0 |
Autonomic Nervous System Diseases/blood/*physiopathology | 2 | 100.0 |
Pulse/drug effects | 2 | 10.0 |
Heart Failure, Congestive/*blood/physiopathology | 4 | 44.0 |
Adenylate Cyclase/antagonists & inhibitors | 2 | 12.0 |
Biological Assay | 4 | 1.0 |
Radioimmunoassay/methods | 9 | 5.0 |
Argipressin/*pharmacology/urine | 3 | 100.0 |
Norepinephrine/*pharmacology | 2 | 10.0 |
Osmosis | 2 | 7.0 |
Radioimmunoassay/*methods | 10 | 13.0 |
*Infant, Newborn | 4 | 8.0 |
Argipressin/*blood/physiology | 2 | 100.0 |
Stress, Psychological/physiopathology | 2 | 16.0 |
*Extracellular Space | 2 | 66.0 |
Adenoma/*secretion | 2 | 7.0 |
Cushing Syndrome/metabolism | 2 | 20.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Pituitary Neoplasms/*secretion | 3 | 6.0 |
Smoking | 2 | 0.0 |
Water-Electrolyte Imbalance/*etiology | 2 | 66.0 |
*Osmolar Concentration | 2 | 50.0 |
Heart Failure, Congestive/drug therapy/*physiopathology | 2 | 22.0 |
Aldosterone/metabolism | 2 | 10.0 |
Immunoenzyme Techniques | 3 | 0.0 |
*Kidney Concentrating Ability | 4 | 80.0 |
Rabbits/immunology | 2 | 2.0 |
Peptides/*blood | 2 | 2.0 |
Diet | 2 | 0.0 |
Oxytocin/*analysis | 2 | 20.0 |
Pulse | 3 | 14.0 |
Regional Blood Flow | 2 | 1.0 |
Vascular Resistance | 2 | 3.0 |
Diabetes Insipidus/metabolism | 3 | 60.0 |
Haplorhini | 2 | 0.0 |
Hypothalamo-Hypophyseal System/*drug effects/secretion | 2 | 100.0 |
Hypothyroidism/*blood/metabolism | 2 | 100.0 |
Protirelin/*diagnostic use/physiology | 2 | 100.0 |
Thyrotropin/*blood | 2 | 1.0 |
Ascites/blood | 3 | 60.0 |
Liver Cirrhosis, Alcoholic/blood/*urine | 2 | 100.0 |
Drug Stability | 2 | 0.0 |
Cushing Syndrome/*metabolism | 2 | 18.0 |
Kidney/drug effects/metabolism | 2 | 12.0 |
Phagocytes/*metabolism | 2 | 11.0 |
MSH/*secretion | 2 | 100.0 |
Delivery, Obstetric | 2 | 5.0 |
Microchemistry | 2 | 6.0 |
Chlorpropamide/pharmacology | 2 | 100.0 |
Diabetes Insipidus/blood/*genetics | 2 | 100.0 |
Hemorrhage/blood | 2 | 28.0 |
Vasopressins/*urine | 2 | 66.0 |
Half-Life | 2 | 0.0 |
*Rest | 2 | 13.0 |
Alcoholic Intoxication/*blood | 2 | 50.0 |
Vasopressins/*analogs & derivatives | 12 | 100.0 |
